HGI 002
Alternative Names: HGI-002Latest Information Update: 12 May 2023
At a glance
- Originator Shenzhen Hemogen
- Class Gene therapies; Stem cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase 0 Alpha-thalassaemia
Most Recent Events
- 12 May 2023 Phase-0 for Alpha-thalassaemia in China (Parenteral) (NCT05851105)
- 08 Mar 2023 Preclinical trials in Alpha-thalassaemia in China (Parenteral), prior to March 2023 (Shenzhen Hemogen pipeline, March 2023)